Liquid chromatography–tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum

Urinovska, R.; Brozmanová, Hana; Sistik, P.; Šilhán, Petr; Kacířová, Ivana; Lemr, Karel; Grundmann, Milan

doi:10.1016/j.jchromb.2012.09.009

Cited by 66 publications

(44 citation statements)

References 40 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean norfluoxetine concentration at the 10-day time point was 282 ng/ml, with the range of 140-479 ± 41 ng/ml, whereas at the 20 and 30 day interval, the mean norfluoxetine levels were 364 and 414 ng/ml, with the range of 74-532 ± 41 and 153-579 ± 46 ng/ml, respectively (Additional file 1: Figure S1B). The serum levels of fluoxetine were within the range reported previously for human serum samples [19]. However, norfluoxetine concentration reached ~ twofold higher levels than in human populations [19], probably due to the differences in metabolic transformation of the parent drug in mice versus humans.…”

Section: Methodssupporting

confidence: 71%

Fluoxetine modulates breast cancer metastasis to the brain in a murine model

et al. 2014

View full text Add to dashboard Cite

BackgroundDespite advances in the treatment of primary breast tumors, the outcome of metastatic breast cancer remains dismal. Brain metastases present a particularly difficult therapeutic target due to the “sanctuary” status of the brain, with resulting inability of most chemotherapeutic agents to effectively eliminate cancer cells in the brain parenchyma. A large number of breast cancer patients receive various neuroactive drugs to combat complications of systemic anti-tumor therapies and to treat concomitant diseases. One of the most prescribed groups of neuroactive medications is anti-depressants, in particular selective serotonin reuptake inhibitors (SSRIs). Since SSRIs have profound effects on the brain, it is possible that their use in breast cancer patients could affect the development of brain metastases. This would provide important insight into the mechanisms underlying brain metastasis. Surprisingly, this possibility has been poorly explored.MethodsWe studied the effect of fluoxetine, an SSRI, on the development of brain metastatic breast cancer using MDA-MB-231BR cells in a mouse model.ResultsThe data demonstrate that fluoxetine treatment increases the number of brain metastases, an effect accompanied by elevated permeability of the blood–brain barrier, pro-inflammatory changes in the brain, and glial activation. This suggests a possible role of brain-resident immune cells and glia in promoting increased development of brain metastases.ConclusionOur results offer experimental evidence that neuroactive substances may influence the pathogenesis of brain metastatic disease. This provides a starting point for further investigations into possible mechanisms of interaction between various neuroactive drugs, tumor cells, and the brain microenvironment, which may lead to the discovery of compounds that inhibit metastasis to the brain.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-598) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodssupporting

confidence: 71%

Fluoxetine modulates breast cancer metastasis to the brain in a murine model

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Eap et al (22) published a GC-MS method for the determination of citalopram, paroxetine, sertraline and their metabolites in plasma after derivatization. We have developed an LC-MS method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum (23). The method can be used for phenotyping, since it enables simultaneous measurement of parent drugs and the main metabolites.…”

Section: Determination Of Psychotropic Drugsmentioning

confidence: 99%

Therapeutic drug monitoring of atypical antipsychotic drugs

2014

Self Cite

View full text Add to dashboard Cite

Schizophrenia is a severe psychiatric disorder often associated with cognitive impairment and affective, mainly depressive, symptoms. Antipsychotic medication is the primary intervention for stabilization of acute psychotic epi sodes and prevention of recurrences and relapses in patients with schizophrenia. Typical antipsychotics, the older class of antipsychotic agents, are currently used much less frequently than newer atypical antipsychotics. Therapeutic drug monitoring (TDM) of antipsychotic drugs is the specific method of clinical pharmacology, which involves measurement of drug serum concentrations followed by interpretation and good cooperation with the clinician. TDM is a powerful tool that allows tailor-made treatment for the specific needs of individual patients. It can help in monitoring adherence, dose adjustment, minimizing the risk of toxicity and in cost-effectiveness in the treatment of psychiatric disorders. The review provides complex knowledge indispensable to clinical pharmacologists, pharmacists and clinicians for interpretation of TDM results.

show abstract

“…Recently, several studies have utilized methods based on liquid chromatography coupled with mass spectrometry (LC-MS/MS) to increase sensitivity in detection with shorter run times (Urinovska et al, 2012, Ansermot et al, 2013. Although LC-MS/MS methods are advantageous in many ways, the expensive instrumentation and decreased accessibility to routine hospital practice and laboratories are their major limitations.…”

Section: Introductionmentioning

confidence: 99%

Concurrent determination of olanzapine, risperidone and 9‐hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study

Kumar¹,

Ramanathan²

2015

Biomedical Chromatography

View full text Add to dashboard Cite

A simple and sensitive ultra-performance liquid chromatography (UPLC) method has been developed and validated for simultaneous estimation of olanzapine (OLZ), risperidone (RIS) and 9-hydroxyrisperidone (9-OHRIS) in human plasma in vitro. The sample preparation was performed by simple liquid-liquid extraction technique. The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C. Quantification was performed on a photodiode array detector set at 277 nm and clozapine was used as internal standard (IS). OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min. The method was validated for selectivity, specificity, recovery, linearity, accuracy, precision and sample stability. The calibration curve was linear over the concentration range 1-100 ng/mL for OLZ, RIS and 9-OHRIS. Intra- and inter-day precisions for OLZ, RIS and 9-OHRIS were found to be good with the coefficient of variation <6.96%, and the accuracy ranging from 97.55 to 105.41%, in human plasma. The validated UPLC method was successfully applied to the pharmacokinetic study of RIS and 9-OHRIS in human plasma.

show abstract

Liquid chromatography–tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum

Cited by 66 publications

References 40 publications

Fluoxetine modulates breast cancer metastasis to the brain in a murine model

Fluoxetine modulates breast cancer metastasis to the brain in a murine model

Therapeutic drug monitoring of atypical antipsychotic drugs

Concurrent determination of olanzapine, risperidone and 9‐hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study

Contact Info

Product

Resources

About